A61P 17 - Drugs for dermatological disorders

Patents for A61P 17 - Drugs for dermatological disorders (106,455)
11/2001
11/22/2001	WO2001088116A2 Method of modulating activation of lymphocytes via modulation of pituitary tumor transforming gene, related screeining methods
11/22/2001	WO2001088103A2 Compositions and methods for tissue dedifferentiation and regeneration
11/22/2001	WO2001088100A1 Novel method of inducing the differentiation of embryonic stem cells into ectodermal cells and use thereof
11/22/2001	WO2001087979A2 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
11/22/2001	WO2001087977A2 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
11/22/2001	WO2001087935A2 Methods of modulating angiogenesis by regulating the expression of pituitary tumor transforming gene (pttg)
11/22/2001	WO2001087928A1 Peptides and derivatives thereof showing cell attachment, spreading and detachment activity
11/22/2001	WO2001087923A1 Therapeutic approaches to diseases by suppression of the nurr subfamily of nuclear transcription factors
11/22/2001	WO2001087890A1 Thienodibenzoazulene compounds as tumor necrosis factor inhibitors
11/22/2001	WO2001087884A2 Polyketide derivatives
11/22/2001	WO2001087870A1 Hydroxamic acid derivatives
11/22/2001	WO2001087846A2 Tricyclic pyrazole derivatives as protein kinase inhibitors
11/22/2001	WO2001087844A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
11/22/2001	WO2001087841A1 Novel polymorph v of torasemide
11/22/2001	WO2001087840A1 Propanoic acid derivatives as integrin receptor antagonists
11/22/2001	WO2001087839A1 Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity
11/22/2001	WO2001087823A1 Novel aryl, alkenyl, and alkynl 4-dedimethylaminotetracycline derivatives
11/22/2001	WO2001087350A2 Treatment of human papillomavirus (hpv)-infected cells
11/22/2001	WO2001087343A2 Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
11/22/2001	WO2001087338A1 Immunomodulatory human mhc class ii antigen-binding polypeptides
11/22/2001	WO2001087337A1 Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
11/22/2001	WO2001087330A2 Compositions and methods for achieving immune suppression
11/22/2001	WO2001087328A2 Interleukin-1 inhibitors in the treatment of diseases
11/22/2001	WO2001087327A1 Method for cell adhesion and wound healing
11/22/2001	WO2001087319A1 Use of a cell extract of at least a plant of the family pontederiaceae as anti-pollution agent
11/22/2001	WO2001087301A1 Methods for treatment of inflammatory diseases
11/22/2001	WO2001087299A1 Aralkyl ester soft drugs
11/22/2001	WO2001087265A2 Pharmaceutical form of administration for peptides, methods for its production and use
11/22/2001	WO2001087254A1 Use of ellagic acid as anti-pollution cosmetic agent
11/22/2001	WO2001087253A1 Use of n,n'-dibenzyl ethylene diamine n,n'-diacetic acid derivatives as anti-pollution agent
11/22/2001	WO2001087236A2 Topical administration of pharmacological compositions for non-systemic treatment of pruritus
11/22/2001	WO2001087234A2 Treatment of autoimmune, proliferative and inflammatory diseases with compositions of non-ionic copolymers
11/22/2001	WO2001087232A2 Allantoin-containing skin cream
11/22/2001	WO2001087039A2 Treatment of neoplasia / transformation using pituitary tumor transforming gene 2
11/22/2001	WO2001055333A8 Methods and materials relating to transforming growth factor alpha-like polypeptides and polynucleotides
11/22/2001	WO2001046128A3 Tryptase inhibitors
11/22/2001	WO2001042246A3 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
11/22/2001	WO2001041534A3 Pseudomycin phosphate prodrugs
11/22/2001	WO2001038355A3 Method of forming a peptide-receptor complex with zsig33 and therapeutic use thereof
11/22/2001	WO2001036462A3 Protein c derivatives
11/22/2001	WO2001034805A3 Human vanilloid receptor gene
11/22/2001	WO2001030781A3 INHIBITORS OF αLβ2 MEDIATED CELL ADHESION
11/22/2001	WO2001027268A3 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
11/22/2001	WO2001025239A3 Oxazinoquinolones useful for the treatment of viral infections
11/22/2001	WO2001014564A3 Polynucleotides expressed in activated t-lymphocytes and proteins encoded thereby
11/22/2001	US20010044451 Tyrosine kinase inhibitors
11/22/2001	US20010044444 Pyrimidine 3-oxide compounds for inducing/stimulating hair growth and/or retarding hair loss
11/22/2001	US20010044442 Dimethoxy quinazolines for treating diabetes
11/22/2001	US20010044436 Bicyclic inhibitors of glycogen synthase kinase 3
11/22/2001	US20010044430 Cosmetic composition containing a steroid and a 2-alkylalkanol or an ester thereof
11/22/2001	US20010044421 Antimutagenic compositions for treatment and prevention of photodamage to skin
11/22/2001	US20010044419 Administering to skin a composition containing deoxyribonucleosides in concentrations sufficient to enhance DNA repair or reduce mutation frequency in a vehicle capable of delivering deoxyribonucleosides to skin cells
11/22/2001	US20010044416 Administering an antigen and a CD4+ T helper (Th2) cell immunostimulatory nucleic acid mucosally or dermally to produce an antigen specific immune response; treating autoimmune diseases, cancer, infections
11/22/2001	US20010044144 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor
11/22/2001	US20010043935 Use of polyamino acid derivatives to treat seborrhoea and the associated skin disorders
11/22/2001	DE10033990A1 Cyclodextrine, die vorzugsweise an ihrer primären Fläche durch Säure- oder Aminfunktionen substituiert sind Cyclodextrins, which are preferably substituted on its primary surface by acid or amine functions
11/22/2001	DE10023484A1 New 2-((cycloalkyl- or heterocyclyl-alkyl)-amino)-benzamide derivatives, are VEGF receptor, KDR kinase and FLT kinase inhibitors useful e.g. for treating tumors, psoriasis, arthritis or renal or ophthalmological diseases
11/22/2001	DE10020667A1 Neue Benzoxazin- und Benzothiazin-Derivate und deren Verwendung in Arzneimitteln New benzoxazine and benzothiazine derivatives and their use in medicaments
11/22/2001	CA2409740A1 Novel aryl, alkenyl, and alkynyl 4-dedimethylaminotetracycline desrivatives
11/22/2001	CA2409703A1 Novel differentiation inducing process of embryonic stem cell to ectodermal cell and its use
11/22/2001	CA2409699A1 Novel polymorph v of torasemide
11/22/2001	CA2409506A1 Method for cell adhesion and wound healing
11/22/2001	CA2409225A1 Tricyclic pyrazole derivatives
11/22/2001	CA2409154A1 Compositions, kits, and methods for identification and modulation of t helper-1 and t helper-2 cells and diseases associated therewith
11/22/2001	CA2409068A1 Novel dual oxidases as mitogenic and endocrine regulators
11/22/2001	CA2409035A1 Hydroxamic acid derivatives
11/22/2001	CA2408830A1 Treatment of human papillomavirus (hpv)-infected cells
11/22/2001	CA2408745A1 Anti-angiogenic polypeptides
11/22/2001	CA2408701A1 Compositions and methods for tissue dedifferentiation and regeneration
11/22/2001	CA2408691A1 Compositions and methods for achieving immune suppression
11/22/2001	CA2408689A1 Allantoin-containing skin cream
11/22/2001	CA2408617A1 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
11/22/2001	CA2408513A1 Immunomodulatory human mhc class ii antigen-binding polypeptides
11/22/2001	CA2408383A1 Use of ellagic acid as anti-pollution cosmetic agent
11/22/2001	CA2408373A1 Therapeutic approaches to diseases by suppression of the nurr subfamily of nuclear transcription factors
11/22/2001	CA2408360A1 Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
11/22/2001	CA2408163A1 Methods for treatment of inflammatory diseases
11/22/2001	CA2407469A1 Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
11/22/2001	CA2407259A1 Polyketide derivatives
11/22/2001	CA2407258A1 Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity
11/22/2001	CA2407099A1 Aralkyl ester soft drugs
11/22/2001	CA2406013A1 Treatment of autoimmune, proliferative and inflammatory diseases with compositions of non-ionic copolymers
11/21/2001	EP1156334A2 Method for screening a substance having promoting activity on hair growth
11/21/2001	EP1156332A2 Assay methods for cyclin dependent kinases
11/21/2001	EP1156049A1 Substituted heterocyclic compounds, their process of preparation and pharmaceutical compositions containing them
11/21/2001	EP1156031A1 Novel compound, polymer prepared from the compound, and composition comprising the polymer
11/21/2001	EP1155686A1 Use og manganese in the treatment of wrinkles
11/21/2001	EP1155685A1 Composition containing manganese
11/21/2001	EP1155014A1 New benzimidazole compounds for use as active therapeutic substances, process for the preparation of these compoudns and pharmaceutical compositions comprising them
11/21/2001	EP1155000A1 2-aminopyridines containing fused ring substituents
11/21/2001	EP1154988A1 Mevinolin derivatives
11/21/2001	EP1154785A2 Inhibitors for use in hemostasis and immune function
11/21/2001	EP1154774A1 Quinazoline derivatives as angiogenesis inhibitors
11/21/2001	EP1154769A1 A novel anti-angiogenic agent comprising at least one kringle region and an upstream pre-activation domain of plasminogen
11/21/2001	EP1154767A1 Substituted stilbene compounds with vascular damaging activity
11/21/2001	EP1154755A1 Liposome formulations
11/21/2001	EP1011649B1 Use of endipalene in the treatment of psoriasis
11/21/2001	EP0952974B1 Biphenyl derivatives substituted by an aromatic or heteroaromatic radical and pharmaceutical and cosmetic compositions containing same
11/21/2001	EP0914319B1 Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists
11/21/2001	EP0536186B1 Bone and cartilage inductive proteins

1 ... 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 ... 1065